骨粗鬆症治療薬の世界市場規模調査＆予測：薬剤タイプ別（副甲状腺ホルモン療法、ビスホスホネート、カルシトニン、RANKL阻害剤、その他の薬剤タイプ）、投与経路別（経口、注射、その他）、地域別分析、2023-2030年

骨粗鬆症治療薬の世界市場は、2022年に約89億3,000万米ドルと評価され、予測期間2023-2030年には3.9%以上の健全な成長率で成長すると予測されています。

骨粗鬆症は、人間の骨の質と密度の低下を特徴とする病状です。さらに、この健康問題によって骨は多孔質になり、よりもろく骨折しやすくなります。この疾患は、副甲状腺ホルモンの過剰によって引き起こされます。その結果、深刻な骨折を引き起こし、患者の健康に害を及ぼします。そのため、この問題は治療が必要であり、それには骨粗鬆症の治療薬を服用する必要があります。RANKリガンド阻害薬、副甲状腺ホルモン治療薬、カルシトニン、選択的エストロゲン阻害薬（SERM）などが市販されています。これらの薬剤は経口投与や静脈内投与などの方法で投与されます。老年人口の急増、座りがちなライフスタイルの採用、ヘルスケア支出の増加、股関節骨折の増加は、推定期間中の市場需要を促進しているいくつかの要因です。

加えて、骨粗鬆症の発生率の増加が、世界中で市場成長を規定する主要な役割を果たしています。骨粗鬆症の有病率は、生活習慣の変化、運動不足、食生活の乱れなどが原因で増加しています。このため、骨粗鬆症治療薬の需要が増加しています。国際骨粗鬆症財団によると、2020年には、50歳以上の男性の5人に1人、女性の3人に1人が骨粗鬆症による骨折を経験する可能性があると推測されます。さらに、国際骨粗鬆症財団（IOF）によると、2019年、欧州における骨粗鬆症性骨折の年間件数は428万件で、これは増加し、2034年には534万件に達すると予測されています。15年間の増加率は、8％（ラトビア）という低い増加率から58％（アイルランド）まで、国によって大きく異なるようです。また、全米骨粗鬆症財団（NOF）によれば、2020年には米国で1,000万人以上が骨粗鬆症と診断されています。その結果、骨粗鬆症患者の増加が市場拡大に大きく寄与しています。さらに、新興市場における高い成長機会や研究開発活動への投資の増加は、予測期間中にさまざまな有利な機会をもたらします。しかし、医薬品承認プロセスに関する厳しい規制と骨粗鬆症治療薬の副作用が、2023-2030年の予測期間を通じて市場成長に課題しています。

骨粗鬆症治療薬の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、骨粗鬆症の罹患率の急増、主要プレイヤーの存在、研究開発投資の増加により、2022年の市場を独占しました。一方、アジア太平洋地域は予測期間中に最も速い成長が見込まれています。骨粗鬆症治療薬の使用に関する意識の高まり、政府のイニシアチブの高まり、股関節骨折の増加、ライフスタイルの変化、ジェネリック医薬品への需要の高まりなどが、同地域の市場需要を大きく促進しています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

• 市場スナップショット
• 世界市場・セグメント別市場推計・予測、2020-2030年
  • 骨粗鬆症治療薬市場：地域別、2020-2030年
  • 骨粗鬆症治療薬市場：薬剤タイプ別、2020-2030年
  • 骨粗鬆症治療薬市場：投与経路別、2020-2030年
• 主要動向
• 調査手法
• 調査前提条件

第2章 骨粗鬆症治療薬の世界市場：定義と範囲

• 調査目的
• 市場の定義と範囲
  • 産業の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 骨粗鬆症治療薬の世界市場力学

• 骨粗鬆症治療薬市場の影響分析（2020～2030年）
  • 市場促進要因
    • 骨粗鬆症患者の増加
    • 股関節骨折の増加
  • 市場の課題
    • 医薬品承認プロセスにおける厳しい規制
    • 骨粗鬆症治療薬の副作用
  • 市場機会
    • 新興市場における高い成長見通し
    • 研究開発活動への投資の増加

第4章 骨粗鬆症治療薬の世界市場：産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォース影響分析
• PEST分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 骨粗鬆症治療薬の世界市場：薬剤タイプ別

• 市場スナップショット
• 骨粗鬆症治療薬の世界市場：薬物タイプ別、実績 - ポテンシャル分析
• 骨粗鬆症治療薬の世界市場：薬剤タイプ別推定・予測：2020-2030年
• 骨粗鬆症治療薬市場、サブセグメント分析
  • 副甲状腺ホルモン療法
  • ビスフォスフォネート
  • カルシトニン
  • RANKL阻害剤
  • その他の薬剤タイプ

第6章 骨粗鬆症治療薬の世界市場：投与経路別

• 市場スナップショット
• 骨粗鬆症治療薬の世界市場：投与ルート別、実績 - ポテンシャル分析
• 骨粗鬆症治療薬の世界市場、投与ルート別推定・予測：2020-2030年
• 骨粗鬆症治療薬市場、サブセグメント分析
  • 経口剤
  • 注射剤
  • その他

第7章 骨粗鬆症治療薬の世界市場：地域別分析

• 主要国
• 主な新興国
• 骨粗鬆症治療薬市場の市場スナップショット、地域別
• 北米
  • 米国
    • 薬剤タイプの推定・予測、2020-2030年
    • 投与経路の推定・予測、2020-2030年
  • カナダ
• 欧州の骨粗鬆症治療薬市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋の骨粗鬆症治療薬市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの骨粗鬆症治療薬市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他中東とアフリカ

第8章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Amgen Inc.
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
    • 最近の動向
  • Eli Lilly and Company
  • F. HOFFMANN-LA ROCHE LTD.
  • Radius Health, Inc.
  • Merck & Co. Inc.
  • Novartis International AG（Sandoz）
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

第9章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Osteoporosis Drugs Market, report scope
• TABLE 2. Global Osteoporosis Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Osteoporosis Drugs Market estimates & forecasts by Drug Type 2020-2030 (USD Billion)
• TABLE 4. Global Osteoporosis Drugs Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
• TABLE 5. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 6. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Osteoporosis Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Osteoporosis Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. U.S. Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 17. U.S. Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. Canada Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 19. Canada Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 20. Canada Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. UK Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 22. UK Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 23. UK Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. Germany Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 25. Germany Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 26. Germany Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. France Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 28. France Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 29. France Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. Italy Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 31. Italy Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 32. Italy Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Spain Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 34. Spain Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 35. Spain Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. RoE Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 37. RoE Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 38. RoE Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. China Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 40. China Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 41. China Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. India Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 43. India Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 44. India Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. Japan Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 46. Japan Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 47. Japan Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. South Korea Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 49. South Korea Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 50. South Korea Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. Australia Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 52. Australia Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 53. Australia Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. RoAPAC Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. Brazil Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 58. Brazil Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 59. Brazil Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Mexico Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 61. Mexico Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 62. Mexico Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. RoLA Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 64. RoLA Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 65. RoLA Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. Saudi Arabia Osteoporosis Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 67. South Africa Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 68. RoMEA Osteoporosis Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. List of secondary sources, used in the study of global Osteoporosis Drugs Market
• TABLE 70. List of primary sources, used in the study of global Osteoporosis Drugs Market
• TABLE 71. Years considered for the study
• TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Osteoporosis Drugs Market, research methodology
• FIG 2. Global Osteoporosis Drugs Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Osteoporosis Drugs Market, key trends 2022
• FIG 5. Global Osteoporosis Drugs Market, growth prospects 2023-2030
• FIG 6. Global Osteoporosis Drugs Market, porters 5 force model
• FIG 7. Global Osteoporosis Drugs Market, pest analysis
• FIG 8. Global Osteoporosis Drugs Market, value chain analysis
• FIG 9. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Osteoporosis Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Osteoporosis Drugs Market, regional snapshot 2020 & 2030
• FIG 15. North America Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
• FIG 17. Asia pacific Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Osteoporosis Drugs Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Osteoporosis Drugs Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Osteoporosis Drugs Market is valued at approximately USD 8.93 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 3.9% over the forecast period 2023-2030. Osteoporosis is a medical condition that is characterized by low bone quality and density in humans. Additionally, this health issue causes the bones to become porous, which makes them more brittle and susceptible to fractures. The disorder is caused by an excess of the hormone parathyroid. The condition results in serious fractures, which are harmful to the patient's health. Because of this, the problem needs to be treated, which involves taking medications for osteoporosis. RANK ligand inhibitors, parathyroid hormone treatment, calcitonin, and selective estrogen inhibitors modulators (SERM) are several medications available in the market. These medications are administered in ways including orally and intravenously. The surge in the geriatric population, adoption of a sedentary lifestyle, increasing healthcare expenditure, and rise in hip fractures are the several factors that are propelling the market demand during the estimated period.

In addition, the increase in the incidences of osteoporosis is playing a major role that is stipulating market growth across the globe. The prevalence of osteoporosis is increasing due to changing lifestyle habits, lack of physical activity, and poor diet. This has led to an increase in the demand for osteoporosis drugs. The International Osteoporosis Foundation stated that in 2020, 1 in 5 men and 1 in 3 women more than the age of 50 are likely to experience osteoporosis fractures in their life. Additionally, according to the International Osteoporosis Foundation (IOF), in 2019, the annual number of osteoporotic fractures in Europe accounted for 4.28 million, which is projected to increase and reach 5.34 million in 2034. The percentage growth during the 15-year period is likely to differ significantly by nation, from a low 8% growth (Latvia) to 58% (Ireland). Also, as per the National Osteoporosis Foundation (NOF), in 2020, over 10 million people in the United States have been diagnosed with osteoporosis, which is common in menopausal women. Consequentially, the rising cases of osteoporosis are significantly contributing to the market expansion. Moreover, the high growth prospects in emerging markets, as well as the increasing investment in R&D activities present various lucrative opportunities over the forecasting years. However, the stringent regulations on the drug approval process and the side effects of osteoporosis drugs are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Osteoporosis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surge in the incidence of osteoporosis, the presence of key players, and growing R&D investment. Whereas, Asia Pacific is expected to grow at the fastest growing over the forecasting years. The growing awareness regarding the use of osteoporosis drugs, rising government initiatives, increase in hip fractures, changing lifestyle, and growing demand for generic drugs are significantly propelling the market demand across the region.

Major market players included in this report are:

• Amgen Inc.
• Eli Lilly and Company
• F. HOFFMANN-LA ROCHE LTD.
• Radius Health, Inc.
• Merck & Co. Inc.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Recent Developments in the Market:

• In August 2021, The Drug Controller General of India (DCGI) granted Enzene Biosciences Ltd. marketing authorization (MA) for their biosimilar medication, denosumab, which is approved for the treatment of adult osteoporosis.

Global Osteoporosis Drugs Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Drug Type, Route of Administration, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• RANKL Inhibitors
• Other Drug Types

By Route of Administration:

• Oral
• Injectable
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Osteoporosis Drugs Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Osteoporosis Drugs Market, by Drug Type, 2020-2030 (USD Billion)
  • 1.2.3. Osteoporosis Drugs Market, by Route of Administration, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Osteoporosis Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Osteoporosis Drugs Market Dynamics

• 3.1. Osteoporosis Drugs Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increase in the incidences of osteoporosis
    • 3.1.1.2. Rising hip fractures
  • 3.1.2. Market Challenges
    • 3.1.2.1. Stringent regulations on drug approval process
    • 3.1.2.2. Side effects of osteoporosis drugs
  • 3.1.3. Market Opportunities
    • 3.1.3.1. High growth prospects in emerging markets
    • 3.1.3.2. Increasing investment in the R&D activities

Chapter 4. Global Osteoporosis Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Osteoporosis Drugs Market, by Drug Type

• 5.1. Market Snapshot
• 5.2. Global Osteoporosis Drugs Market by Drug Type, Performance - Potential Analysis
• 5.3. Global Osteoporosis Drugs Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
• 5.4. Osteoporosis Drugs Market, Sub Segment Analysis
  • 5.4.1. Parathyroid Hormone Therapy
  • 5.4.2. Bisphosphonates
  • 5.4.3. Calcitonin
  • 5.4.4. RANKL Inhibitors
  • 5.4.5. Other Drug Types

Chapter 6. Global Osteoporosis Drugs Market, by Route of Administration

• 6.1. Market Snapshot
• 6.2. Global Osteoporosis Drugs Market by Route of Administration, Performance - Potential Analysis
• 6.3. Global Osteoporosis Drugs Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 6.4. Osteoporosis Drugs Market, Sub Segment Analysis
  • 6.4.1. Oral
  • 6.4.2. Injectable
  • 6.4.3. Others

Chapter 7. Global Osteoporosis Drugs Market, Regional Analysis

• 7.1. Top Leading Countries
• 7.2. Top Emerging Countries
• 7.3. Osteoporosis Drugs Market, Regional Market Snapshot
• 7.4. North America Osteoporosis Drugs Market
  • 7.4.1. U.S. Osteoporosis Drugs Market
    • 7.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
  • 7.4.2. Canada Osteoporosis Drugs Market
• 7.5. Europe Osteoporosis Drugs Market Snapshot
  • 7.5.1. U.K. Osteoporosis Drugs Market
  • 7.5.2. Germany Osteoporosis Drugs Market
  • 7.5.3. France Osteoporosis Drugs Market
  • 7.5.4. Spain Osteoporosis Drugs Market
  • 7.5.5. Italy Osteoporosis Drugs Market
  • 7.5.6. Rest of Europe Osteoporosis Drugs Market
• 7.6. Asia-Pacific Osteoporosis Drugs Market Snapshot
  • 7.6.1. China Osteoporosis Drugs Market
  • 7.6.2. India Osteoporosis Drugs Market
  • 7.6.3. Japan Osteoporosis Drugs Market
  • 7.6.4. Australia Osteoporosis Drugs Market
  • 7.6.5. South Korea Osteoporosis Drugs Market
  • 7.6.6. Rest of Asia Pacific Osteoporosis Drugs Market
• 7.7. Latin America Osteoporosis Drugs Market Snapshot
  • 7.7.1. Brazil Osteoporosis Drugs Market
  • 7.7.2. Mexico Osteoporosis Drugs Market
• 7.8. Middle East & Africa Osteoporosis Drugs Market
  • 7.8.1. Saudi Arabia Osteoporosis Drugs Market
  • 7.8.2. South Africa Osteoporosis Drugs Market
  • 7.8.3. Rest of Middle East & Africa Osteoporosis Drugs Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Company 1
  • 8.1.2. Company 2
  • 8.1.3. Company 3
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Amgen Inc.
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Recent Developments
  • 8.3.2. Eli Lilly and Company
  • 8.3.3. F. HOFFMANN-LA ROCHE LTD.
  • 8.3.4. Radius Health, Inc.
  • 8.3.5. Merck & Co. Inc.
  • 8.3.6. Novartis International AG (Sandoz)
  • 8.3.7. Pfizer Inc.
  • 8.3.8. Sun Pharmaceutical Industries Ltd.
  • 8.3.9. Takeda Pharmaceutical Company Limited
  • 8.3.10. Teva Pharmaceutical Industries Ltd.

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption